Dysgeusia News and Research

RSS
BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech to present new data for targeted cancer medicines at 46th ASCO

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Chantix new quit smoking drug approved

Chantix new quit smoking drug approved